Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Absci Corporation - Common Stock (NQ: ABSI )

3.970 +0.750 (+23.29%)
Streaming Delayed Price Updated: 9:54 AM EST, Jan 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Absci Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference
From Absci Corporation
Via GlobeNewswire
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Cathie Wood's Ark Invest Buys Into Defense And Energy Stocks Amid Trump's Inaugural Policies
Cathie Wood-led Ark Invest made significant trades involving ACCD, DE, NTLA, PATH, CCJ, OKLO, ILMN, ESLT, and ABSI. 
Via Benzinga
Topics Government
Exposures Political
Absci Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class... 
From Absci Corporation; Owkin
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
AAR Posts Upbeat Results, Joins AngioDynamics, eBay, Cal-Maine Foods And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Absci Stock Jumps As AMD Invests $20M To Boost AI Drug Discovery
Absci shares are rising after announcing a strategic collaboration with Advanced Micro Devices Inc. The partnership will enhance Absci's AI drug discovery capabilities using AMD Instinct accelerators... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery
$20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software 
From Absci Corporation
Via GlobeNewswire
Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health
Collaboration leverages Absci’s leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applications 
From Absci Corporation; Invetx
Via GlobeNewswire
Absci to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Absci Corporation
Via GlobeNewswire
Absci Highlights Progress and Updates Across Proprietary Pipeline and Leading AI Platform at 2024 R&D Day
From Absci Corporation
Via GlobeNewswire
Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Via Benzinga
United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference
From Absci Corporation
Via GlobeNewswire
Absci Reports Business Updates and Third Quarter 2024 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
Absci to Host R&D Day on December 12, 2024
From Absci Corporation
Via GlobeNewswire
Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI
Collaboration brings together Absci’s Generative AI drug creation platform with Twist’s DNA synthesis platform to accelerate the design of a novel therapeutic antibody 
From Absci Corporation
Via GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024
From Absci Corporation
Via GlobeNewswire
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... 
Via Talk Markets
Topics Economy
Exposures Economy
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular growth investor keeps adding to some of her favorite falling stocks. 
Via The Motley Fool
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. 
Via Talk Markets
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
ABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q2 2024
ABSI stock results show that Absci missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.